Limitations, agreements, and source contact

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers · Source last updated 2022-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

limitations And Caveats

description

Early termination leading to small numbers of participants analyzed.

point Of Contact

email

info@silverbacktx.com

organization

Silverback Therapeutics, Inc.

phone

206-456-2900

title

Chief Scientific Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice